2018 Press Releases

Press Releases | In the News

This section and the included press releases are presented for historical purposes only. Press releases and other documents speak only as of the date thereof.

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle
10/08/18Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan
Expanded license agreement adds SB206 for the treatment of viral skin infections Novan to receive upfront cash consideration of approximately 1.25 billion JPY (~$11.0 million), payable over the next 12 months Milestone and royalty payments due with clinical, regulatory and commercial progression Japan, the world’s 2nd largest dermatology market, remains a strategic focus for Novan Novan continues to explore additional geographic markets and other business opportunities MORRISVIL... 
10/01/18Novan’s Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November
Trial enrollment completed meaningfully ahead of schedule Top line results targeted to be communicated no later than mid-November Favorable and consistent safety profile of SB206 enabled escalation to highest, 12% dose MORRISVILLE, N.C., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that enrollment in the Company's Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum cont... 
09/24/18Novan Receives FDA Guidance for SB204 and Acne Indication
Written minutes received from Type C meeting with FDA Moderate-to-severe patient pathway re-affirmed Additional insights gained around the severe patient sub-population MORRISVILLE, N.C., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced receipt of written meeting minutes from a Type C meeting held with the U.S. Food and Drug Administration (FDA) in the second quarter of 2018. As previously communicated, receipt of the meeting mi... 
08/20/18Novan Announces Promising Clinical Results with SB414
In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant biomarker changes suggesting a topical nitric oxide therapeutic has the potential to realize disease modification The combination of clinical and biomarker evidence supports progressing nitric oxide-based treatments for multiple inflammatory skin diseases, including, but not limited to, atopic dermatitis, psoriasis and acne rosacea These outc... 
08/08/18Novan Provides Business Update via 10-Q, Adopts Incentive Plan and Agrees to CEO Contract
Company provides a comprehensive business update via its second quarter 2018 Form 10-Q filing New incentive plan is aligned with the achievement of two specific stockholder value targets and is intended to replace annual employee equity grants CEO employment contract agreed; foundation centered on creating stockholder value MORRISVILLE, N.C., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today provided a comprehensive business update in its For... 
06/13/18Novan to Participate in Upcoming Investor Conferences
MORRISVILLE, N.C., June 13, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that members of management are scheduled to attend the 2018 Cantor Dermatology & Aesthetics Summit and the 2018 JMP Securities Life Sciences Conference, each in New York, N.Y., on June 19 and June 20 and 21, respectively. Dr. Nathan Stasko, President and Chief Scientific Officer, is scheduled to participate in a panel session and members of management are expecte... 
06/01/18Novan Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MORRISVILLE, N.C., June 01, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today reported that the Compensation Committee of Novan’s Board of Directors granted stock options to purchase an aggregate of 100,500 shares of its common stock to four newly-hired employees with a grant date of May 31, 2018.  The stock options were granted as inducements material to the new employees entering into employment with Novan in accordance with Nasdaq Listing Rule 5635(c)(4). ... 
05/17/18SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment
Novan to Present Clinical Data from SB208 Onychomycosis Development Program at International Investigative Dermatology Meeting MORRISVILLE, N.C., May 17, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that data from the Company’s onychomycosis development program with SB208 gel demonstrated an enhanced nail growth rate in adult females and will be presented May 19, 2018 at the International Investigative Dermatology meeting in Orlando, Florida. ... 
05/15/18Novan Provides Update on SB414 Inflammatory Skin Disease Development Program
SB414 – Nitric Oxide-Releasing Cream – Safe and Well-Tolerated in Psoriasis Phase 1b Trial Preclinical Data with SB414 Targeting Key Inflammatory Cytokines IL-4 and IL-13 in Atopic Dermatitis to be presented at International Investigative Dermatology Meeting MORRISVILLE, N.C., May 15, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today is providing an update on the SB414 nitric oxide-releasing cream product candidate and its application to two therapeutic ... 
04/12/18Novan Advances Organization and Strengthens Leadership Team
CEO Role No Longer “Interim” Clinical Operations Role Established Finance Team Positioned for the Future MORRISVILLE, N.C., April 12, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced a number of key leadership and talent advancements that add to the existing foundation of the Company and enable its continued progress across key areas. Kelly Martin, who was appointed interim Chief Executive Officer (CEO) in June of 2017, will no longer be... 
03/29/18Novan Announces Corporate Update Conference Call and Webcast
MORRISVILLE, N.C., March 29, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Thursday, April 12, at 8:30 a.m. Eastern Time to provide an update on the Company’s activities and progress. A moderated question and answer session will be available after the update. Callers should dial in approximately 10 minutes prior to the start of the call. No reservation is necessary to participate on the call. The ph... 
02/21/18Dr. Eugene Sun Appointed to Novan Board of Directors
Complements existing Board expertise as 30-year clinician, drug developer and former biopharmaceutical CEO Will provide expert perspective on the clinical application of the underlying nitric oxide science Will chair newly formed Research and Development Committee   MORRISVILLE, N.C., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Eugene Sun, M.D., has been appointed to the Company’s Board of Directors, effective Feb... 
02/13/18Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne
Late-breaking Presentation by Dr. Adelaide Hebert at 2018 AAD Annual Meeting MORRISVILLE, N.C., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that data from the Company’s two Phase 3 clinical trials and long-term safety trial with SB204 for the treatment acne vulgaris will be presented during a Late-breaking Research forum at the 2018 Annual Meeting of the American Academy of Dermatology, or AAD, in San Diego, California. Newly repor... 
01/25/18Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206
MORRISVILLE, N.C., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the first patient has been dosed in the Company's Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum, a contagious skin infection caused by the molluscipoxvirus. There is currently no FDA-approved treatment for the molluscum indication."Broadening Novan's clinical development pipeline to include the ... 
01/11/18Novan Announces Closing of Offering of Common Stock and Warrants
MORRISVILLE, N.C., Jan. 11, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced that it has closed its previously announced underwritten public offering.  The terms of the completed offering are consistent with the terms which were outlined in the Company's press release on January 5, 2018.  The net proceeds to the Company from this offering are expected to be approximately $35.2 million, after deducting underwriting discounts and commissions and ot... 
01/11/18Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference
Topical Nitric Oxide-Releasing Gel Shows Antifungal Activity in Tinea Pedis Infections MORRISVILLE, N.C., Jan. 11, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Phase 2 efficacy and safety data for SB208, a topical, silicone-based gel under development for the treatment of fungal infections of the skin and nails, such as tinea pedis, or athlete’s foot, and onychomycosis, will be presented at the Winter Clinical Dermatology Conference to be ... 
01/05/18Novan Announces Pricing of $38.0 Million Offering of Common Stock and Warrants
MORRISVILLE, N.C., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's underwritten offering of 10 million shares of its common stock and accompanying warrants to purchase up to 10 million shares of common stock with an exercise price of $4.66. The shares and warrants are being sold at a public offering price of $3.80 per share and accompanying warrant. The gross proceeds from this offering to Novan are expected to... 
01/04/18Novan Announces Proposed Public Offering of Common Stock and Warrants
MORRISVILLE, N.C., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering. Piper Jaffray & Co. is acting as the sole book-running manager for the offering. The securities described above are being offered by Novan pursuant to a shelf registrat...